Home/NLS Pharmaceutics/Chris Posner

CP

Chris Posner

Former Chairman of the Board

NLS Pharmaceutics

Therapeutic Areas

Central Nervous System (CNS)Sleep-Wake Disorders

NLS Pharmaceutics Pipeline

Drug	Indication	Phase
Mazindol ER (NLS-4 / Quilience®)	Narcolepsy (Type 1 & 2)	Phase 3
Mazindol ER (NLS-4)	Attention-Deficit/Hyperactivity Disorder (ADHD)	Phase 2

Leadership Team at NLS Pharmaceutics

Chief Executive Officer

Chief Scientific Officer

View full NLS Pharmaceutics profile